Starwatch: Boötes, the herdsman ploughing the heavens
This week, we track down another prominent constellation in the northern hemisphere's spring night sky: Boötes, the herdsman. Listed as part of the 48 constellations described by Ptolemy in the 2nd century, it is now one of the International Astronomical Union's 88 official constellations.
Although known as the herdsman, some stories associated with the constellation depict him as more of a ploughman, driving the constellation of Ursa Major, the great bear, around the pole. In these stories, Ursa Major is changed into an oxen and plough.
The nearby constellation of Canes Venatici, the hunting dogs, is also said to be associated with Boötes. On many old star maps, he is depicted as holding these dogs on a leash.
The chart shows the view looking south-east from London at 22.00BST on 19 May, although the view will remain essentially unchanged all week.
The brightest star in Boötes is the red giant star Arcturus, which is the fourth brightest star in the night sky. Although it has about the same mass as our sun, it has swollen to 25 times its size and now pumps out around 170 times more light.
Boötes is also visible from the southern hemisphere, where it will appear quite close to the northern horizon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
3 hours ago
- Medical News Today
Colon cancer: Exercise as important as drugs in preventing recurrence
Could exercise be 'better than a drug' at preventing colon cancer recurrence? Image credit: Connect Images/. Colorectal cancer is the third most common cancer worldwide, and the second leading cause of cancer deaths. Treatments include surgery, radiotherapy and chemotherapy. After initial treatment, people are advised to follow a healthy lifestyle, often in conjunction with further drug treatments to try and reduce the chance of recurrence. Now, a study has found that a structured exercise program could be more effective than drug treatments in preventing colon cancer recurrence. Patients following a supervised exercise program had a 28% lower risk of recurrence, and a 37% lower risk of death from any cause than those who were not. Now, a study led by Canadian scientists has found that a structured exercise program following surgery and chemotherapy for colon cancer reduced patients' chance of cancer recurring by 28% compared with patients given only health advice. Experts have said these results suggest exercise could be 'better than a drug' at preventing colon cancer recurrence. Speaking to the Science Media Centre, David Sebag-Montefiore, MB BS, MRCP, FRCP, the Audrey and Stanley Burton Professor of Clinical Oncology and Health Research, University of Leeds, United Kingdom, who was not involved in the trial, commented that: 'This is excellent news for future patients with bowel cancer and is likely to bring additional health benefits […[ The great appeal of a structured moderate intensity exercise is that is offers the benefits without the downside of the well-known side effects of our other treatments.' All those enrolled in the trial, between 2009 and 2024, had undergone surgery for stage 3 or high-risk stage 2 colon cancer, followed by adjuvant chemotherapy to help prevent the cancer returning. They ranged in age from 19 to 84 years, with a median age of 61. Most participants had a body mass index (BMI) indicating overweight or obesity, and none exercised for more than 150 minutes per week before the trial. Researchers randomly assigned all participants to one of two groups. The exercise group — made up of 445 patients — worked with a certified physical activity consultant for 3 years. For the first 6 months the consultants saw them every week, then fortnightly for the second 6 months, and monthly for next 2 years. These participants could choose the type, frequency and intensity of aerobic exercise, but the aim was to achieve the equivalent of 3-4 brisk 45-60 minute walks a week. The health-education group (444 patients) received general health-education materials promoting physical activity and healthy nutrition in addition to standard surveillance. At a median follow-up of 7.9 years, 93 people in the exercise group and 131 in the health-education group had experienced a recurrence of their cancer, a new primary cancer, or had died. In total, 107 died from any cause — 41 in the exercise group, 66 in the health-education group. People in the exercise group did not lose weight, but saw a general improvement in physical functioning and significantly longer disease-free survival, with an annual incidence of recurrence, new primary cancer, or death of 3.7%, compared with 5.4% in the health-education group. In the exercise group, 80.3% of patients were disease-free after 5 years, compared with 73.9% of the health-education group. Lead author on the study, Kerry S. Courneya, PhD, Professor and Canada Research Chair in Physical Activity and Cancer at the University of Alberta in Edmonton, Canada, told Medical News Today that the most important finding of their study was the overall improvement in survival. Julie Gralow, MD, Chief Medical Officer of the American Society of Clinical Oncology (ASCO), who was not involved in the trial, said the findings suggest that exercise could be 'better than a drug' for cancer patient outcomes, because it does not have the related side effects. However, she cautioned: 'I did not mean to suggest that we omit drugs in favor of exercise, my intention was to compare the magnitude of benefit we get from standard therapies to what exercise achieved in terms of reduction of recurrences and deaths, also taking toxicity into account.' She added that while there were effective drugs that help prevent recurrence in patients with particular mutations for colon cancer, 'exercise's benefit in colon cancer patients is not restricted to these specific mutations.' Courneya emphasized the benefits of their program: 'The 'side effects' of exercise are almost all good (fitter, stronger, less fatigue, less depression, lower [cardiovascular disease] risk, etc.). I think exercise keeps having an effect on new primary cancers and possibly other causes of death. Intervention participants were still doing more exercise than health education at years 4 and 5.' A supervised exercise program can also be much cheaper than medication. 'The [physical activity] intervention was maybe 3,000 to 5,000 [Canadian dollars] whereas it is not uncommon for some cancer drugs to be 10s of thousands and even reach 100,000,' Courneya added. Vicky Coyle, U.K. lead researcher for the trial and Clinical Professor at Queen's University Belfast, Northern Ireland, told MNT that: 'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer. We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate.' Joe Henson, PhD, Associate Professor in Lifestyle Medicine at the University of Leicester, who led exercise sessions in Leicester, U.K. for the trial, highlighted the need for support. 'Despite its proven benefits, many people still face barriers to engaging in regular exercise. This study shows how important it is to make exercise advice a routine part of cancer care and to offer people tailored support,' Henson told us. Although she emphasizes the importance of exercise to her own patients, Gralow noted that implementing exercise programs like those in this study could be difficult: 'I question whether most clinics have enough personnel to accommodate this number of visits (especially since prior observational data suggests many other cancer types — including common ones like breast and prostate cancer — benefit from exercise). I also question whether all or even most patients are willing to come in this often.' 'So,' she said, 'we need to find alternative ways to support our patients in incorporating exercise into their lives that do not require clinic visits but do provide regular support and encouragement. And we need to make sure we, the clinicians, are recommending this (a prescription for exercise!).' Colorectal Cancer Cancer / Oncology Sports Medicine / Fitness
Daily Mail
3 hours ago
- Daily Mail
Prescription pill taken by 9million is linked to devastating motor neurone disease, researchers find
Antidepressants, taken by some 8.6 million people in the UK, could raise the risk of motor neurone disease, a major study has suggested. Scandinavian researchers also found that other commonly prescribed drugs, like anxiolytics used to treat anxiety disorders, sleeping pills and sedatives were also linked to an increased risk of the disabling condition. Motor neurone disease, of which amyotrophic lateral sclerosis (ALS) is the most common form, is an incurable, muscle-wasting condition that eventually stops a patient from being able to move, talk and even eat. Now, research has suggested that being prescribed any of these medications just twice over the course of a lifetime could raise the chance of developing the condition by up to 34 per cent. Scientists found the risk remained even if the drugs were taken more than five years before diagnosis. However other scientists have urged caution over the results of the study, suggesting the link lies with the fact mental health patients are more likely to develop MND, rather than medication. Professor Ammar Al-Chalabi, a specialist in complex disease genetics at King's College London warned: 'Association is not causation. That is especially important here. 'We already know that some of the genetic variants that nudge people towards schizophrenia for example, overlap with variants that nudge people towards ALS. 'It may not be use of the medication that increases ALS risk, but that the need for the medication is a signal that someone is already at increased genetic risk.' The authors of the study, from various Scandinavian institutions, note that depression, anxiety, and sleep disturbances have been shown to have 'detrimental effects' on brain cells, resulting in 'structural brain change concurrent with ALS'. MND, which includes ALS, is a progressive disease that affects around 5,000 adults in the UK, and was famously suffered by the physicist Stephen Hawking. In the study, which was conducted in Sweden, experts looked at 1,057 patients with an average age of 67, who were diagnosed with the disease between January 2015 and July 2023, as well as medications they had taken. Researchers followed the patients for an average of 1.33 years after their diagnosis. They matched these patients with a group of healthy controls to look for differences that could contribute to the disease. Writing in the journal JAMA open network, the researchers found prescribed use of anxiolytics was associated with 34 per cent increased risk of developing MND. Taking antidepressants, meanwhile, was linked with a 26 per cent raised chance, and sedatives and sleeping pills 21 per cent. The use of antidepressants pre-diagnosis in particular was also associated with a faster rate of functional decline. Lead author, Dr Charilaos Chourpiliadis, said that more work still needs to be done to understand the link. However, he said: 'Closer monitoring in younger patients with psychiatric symptoms might lead to an earlier ALS diagnosis.' Dr Brian Dickie, chief scientist at MND Association also flagged that the study may be flawed, because the most common genetic risk factor for ALS—a repeat expansion in the C9orf72 gene—is most prevalent in the Scandinavian population. 'A study in the Swedish population will most likely have a higher proportion of people with this particular genetic form of the disease,' he explained. 'Not only would higher use of psychiatric medication be likely, but this genetic form is also linked with faster progression and shorter survival, which could explain the association between psychiatric medication and more aggressive disease.'
The Independent
4 hours ago
- The Independent
Fin removed from submarine as disposal reaches ‘significant marker'
A 'significant marker' in the progress of a submarine dismantling initiative has been completed, as the first vessel to be stripped down had its fin cut and removed. The Defence Nuclear Enterprise (DNE) submarine dismantling project announced on Wednesday that demonstrator sub Swiftsure has had its fin removed, a major milestone as the vessel prepares to be fully dismantled by the end of 2026. The work is the world's first full dismantling of a nuclear-powered submarine using a novel and environmentally-responsible method, and it is taking place in Rosyth Dockyard, Fife. The DNE said more than 500 tonnes of waste has been removed and recycled from the sub, and 90% of its total weight is expected to be recycled. With Swiftsure acting as a guinea pig, the DNE aims to develop a blueprint for the recycling of future decommissioned pressurised water reactor one subs. High quality steel taken from the first vessel is already being repurposed for future subs. The fin removal was delivered by the DNE alongside Babcock and Defence Equipment and Support's Defence Recycling and Disposals Team (DRDT). Lorraine Russell, senior responsible owner for the submarine disposals programme, said: 'The project showcases our commitment to sustainable disposal practices. 'By recycling materials wherever possible, we're ensuring these vessels that served the nation so well continue to provide value even after decommissioning.' Alistair Hughes, head of DRDT, said: 'This sustainable solution has shown how we can extract the maximum value from surplus assets and improve defence's supply-chain resilience, whilst ensuring national security and prosperity remains at the core of what we do.' Sir Chris Gardner, chief executive of the Submarine Delivery Agency, said: 'To see the fin of Swiftsure removed is a significant marker of progress in the DNE's submarine dismantling project. 'Our colleagues continue to work tirelessly alongside our industry partners in Rosyth to deliver a proven dismantling method using this demonstrator vessel. My thanks go to everyone involved in this ground-breaking work.' Scottish Secretary Ian Murray said: 'This is another fantastic example of how world-leading Scottish expertise plays such a vital role in the UK's defence. 'Around 25,600 jobs across Scotland are supported by an annual multi-billion-pound Ministry of Defence investment – with 200 highly-skilled roles in Rosyth involved in the submarine dismantling project. 'National security and environmental responsibility are at the heart of our commitment to act as a responsible nuclear operator – a technology which will play a key role in the UK Royal Navy's submarine fleet keeping us safe for years to come. 'Just this week as part of the strategic defence review (SDR), the Prime Minister came to Scotland to announce up to 12 new nuclear-powered attack subs, building on the £15 billion investment set out for the UK's sovereign nuclear warhead programme. 'Scotland has always been at the beating heart of the UK's defence and security and the SDR will restore Britain's readiness, deter our adversaries and help drive economic growth across the UK, as part of our Plan for Change.'
